Basking Biosciences, Inc. Asset Profile

= Subscriber Access Only

You are viewing a preview of this profile. Request a Preqin Pro demo for full access to all profiles and underlying data.

Year established

2019

Location

OH US

Primary Industry

Healthcare Specialists

About

Founded in 2019 and based in Ohio, US, Basking Biosciences, Inc., operates as a healthcare specialist that develops a thrombolytic therapy for acute ischemic stroke. The company was co-founded by Dr. Bruce Sullenger of Duke University and Dr. Shahid Nimjee of The Ohio State University founded the company. Mr. Richard Shea is the CEO of the company. The company developed DTRI-025 in Q4 2020. In December 2020, the company raised USD 5.4 million in seed funding from investors Rev1 Ventures, Broadview Ventures and Viva BioInnovator. The company focuses on exploiting the properties of RNA biochemistry to develop aptamers with high affinity and specificity against proteins involved in coagulation and hemostasis. The company develops the first reversible thrombolytic therapy for Acute Ischemic Stroke (AIS). The solution of company includes DTRI-031 and it can inhibits von Willebrand Factor (vWF). And its solution DTRI-025 is continuing IND-enabling development.

Current Investors

Broadview Ventures, Rev1 Ventures, Viva Biotech (Shanghai) Ltd.

Request a demo to show more

Primary Industry

Healthcare Specialists

Sub Industries

Cardiology

Website

www.baskingbiosciences.com

Verticals

HealthTech

Company Stage

Series B

Total Amount Raised

Subscriber access only

Time to go Pro

Get Preqin Pro for unrestricted access to 600,000+ detailed profiles on fund managers, investors, funds, companies, and other alternative asset players. Unlock exclusive data on future plans, company financials, fundraising history, track records, and more.